Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-04-15
2009-10-06
Kolker, Daniel E. (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S501000
Reexamination Certificate
active
07598048
ABSTRACT:
The invention provides a method for screening for a compound for modulating circadian rhythm. The method involves (a) providing a compound that is a Prokineticin 2 (PK2) receptor antagonist or agonist; and (b) determining the ability of the compound to modulate one or more indicia of circadian rhythm function, wherein a compound that modulates one or more indicia of circadian rhythm function is identified as a compound for modulating circadian rhythm. The invention also provides a mouse PK2 receptor nucleic acid, polypeptide and related compositions. Further provided is a method for modulating circadian rhythm of an animal, which involves administering an effective amount of a PK2 receptor antagonist or agonist to an animal. Also provided is an isolated nucleic acid comprising a PK2 gene promoter operatively linked to a heterologous nucleotide sequence.
REFERENCES:
patent: 5545549 (1996-08-01), Gerald et al.
patent: 5621079 (1997-04-01), Cascieri et al.
patent: 2003/0235535 (2003-12-01), Zhou et al.
patent: 2004/0241757 (2004-12-01), Matsumoto et al.
patent: 2006/0172935 (2006-08-01), Zhou et al.
patent: WO 95/35320 (1995-12-01), None
patent: 9846620 (1998-10-01), None
patent: WO 98/46620 (1998-10-01), None
patent: WO 02/00711 (2002-01-01), None
Dunlap 1999. Cell 96:271-290.
Mintz 1999. Journal of Neuroscience 19:5124-5130.
Schwartz 1987. Proc Natl Acad Sci USA 84:1694-1698.
Akiyama 1999. Journal of Neuroscience 19:1115-1121.
Harrington 1997. Neuroreport 8:2677-2680.
Huhman 1996. Neuroreport 7:1249-1252.
Sweetnam 1995. Chapter 17 in Burger's Medicinal Chemictry and Drug Discovery, Fifth Edition, vol. 1, pp. 697-731.
Lowrey 2000. Science 288:483-491.
Turek et al. 1995. Frontiers in Neuroendocrinology 16:191-223.
Edelstein 2001. Brain Research 918:107-112.
Mrosovsky 1999. Chronobiology International 16:415-429.
Silver et al. 1996 Nature 382:810-813.
Reppert 2000. Seminars in Perinatology 24:243-246.
Jud et al. 2005. Biol. Proced. Online 7:101-116.
Li et al. 2006. Journal of Neuroscience 26:11615-11623.
Levine et al. 2002. Signal analysis of behavioral and molecular cycles. BMC Neuroscience 3:1-25.
Albers et al. 1984 Science 223:833-835.
Stoynev et al. 1996. Acta Physiol Pharmacol Bulg 22:39-43.
Harrington, Mary E. and Hoque, Sabina, “NPY Opposes PACAP phase shifts via receptors different from those involved in NPY Phase Shifts”,Neuroreport, vol. 8, pp. 2677-2680, 1997.
Huhman, Kim L. et al., “Neuropeptide Y phase shifts circadian rhythms in vivo via a Y2receptor”,Neuroreport, vol. 7, pp. 1249-1252, 1996.
Lowrey, Phillip L. et al., “Positional Syntenic Cloning and Functional Characterization of the Mammalian Circadian Mutationtau ”, Science, vol. 288, pp. 483-491, 2000.
Sweetnam, Paul M. et al., “Mass Ligand Screening as a Tool for Drug Discovery and Development”,Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1, Chapter 17, pp. 697-731, 1995.
Boer, G. J. et al., “Vasopressin-Deficient Suprachiasmatic Nucleus Grafts Re-Instate Circadian Rhythmicity in Suprachiasmatic Nucleus-Lesioned Arrhythmic Rats”,Neuroscience, vol. 89, pp. 375-385, 1999.
Cheng, M. Y. et al., “Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus”,Nature, vol. 417, pp. 405-410, 2002.
Jin, X. et al., “A Molecular Mechanism Regulating Rhythmic Output from the Suprachiasmatic Circadian Clock”,Cell, vol. 96, pp. 57-68, 1999.
Kalsbeeck, A. et al., “A Diurnal Rhythm of Stimulatory Input to the Hypothamamo-Pituitary-Adrenal System as Revealed by Timed Intrahypothalamic Administration of the Vasopressin V1 Antagonist”,The Journal of Neuroscience, vol. 17, pp. 5555-5565, 1996.
Kalsbeek, A. et al., “Vasopressin-containing neurons of the suprachiasmatic nuclei inhibit corticosterone release”,Brain Research, vol. 580, pp. 62-67, 1992.
Li et al., “Identification of Two Prokineticin cDNAs: Recombinant Proteins Potently Contract Gastrointestinal Smooth Muscle”,Molecular Pharmacology, 59:692-698 (2001).
Lin et al., “Identification and Molecular Characterization of Two Closely Related G Protein-Coupled Receptors Activated by Prokineticins/Endocrine Gland Vascular Endothelial Growth Factor”,The Journal of Biological Chemistry, 277(22):19276-19280 (2002).
Melchiorri et al., “The Mammalian Homologue of the Novel Peptide Bv8 is Expressed in the Central Nervous System and Supports Neuronal Survival by Activation the Map Kinase/PI-3-Kinase Pathways”,European Journal of Neuroscience, 13:1694-1702 (2001).
Parker et al., “Y-Receptor-Like Genes GPR72 and GPR73: Molecular Cloning, Genomic Organization and Assignment to Human Chromosome 11q21.1 and 2p14 and Mouse Chromosome 9 and 6”,Biochimica et Biophysica Acta, 1491:369-375 (2000).
Bullock Clayton M.
Zhou Qun-Yong
DLA Piper (LLP) US
Kolker Daniel E.
The Regents of the University of California
LandOfFree
Screening methods for identifying agents that modulate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening methods for identifying agents that modulate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening methods for identifying agents that modulate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4142439